BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B. According to GlobalData, Phase II drugs for Hepatitis B have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BW-20507’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BW-20507 is under development for the treatment of chronic hepatitis B virus (HBV) infection. The therapeutic candidate is administered through subcutaneous route in the form of solution.
Argo Biopharma Australia overview
Argo Biopharma Australia (Argo Biopharma) is an healthcare service provider which is specialized in research, development and offers other related services. Argo Biopharma is headquartered in Adelaide, South Australia, Australia.
For a complete picture of BW-20507’s drug-specific PTSR and LoA scores, buy the report here.